Antigenic targets for renal cell carcinoma immunotherapy

Bibliography

• BUKOWSKI RM: Immunotherapy in renal cell carcinoma. Oncology (1999) 13(6):801–810.
   PubMed Web of Science ®Google Scholar
• STEINMAN RM: The dendritie cell system and its role in immunogenicity. Anna. Rev Immunol (1991) 9:271–296.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA: A new era for cancer immunotherapy based on the genes thatencode cancer antigens. Immunity (1999) 10(3):281–287.
   PubMed Web of Science ®Google Scholar
• TSO CL, ZISMAN A, PANTUCK A et al:Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/ monocyte-colony stimulating factor.Cancer Res. (2001) 61(21):7925–7933.
   PubMed Web of Science ®Google Scholar
• •This work details a clinical trial of a chimeric fusion protein comprising G250 and GM-CSF in RCC patients, in which T cell responses were induced againstG250/carbonic anhydrase IX antigen. Studies have shown that the G250 antigen contains a number of defined T cell epitopes. Vaccination with G250/GM-CSF fusion protein not only elicited a CTL response, but also primed T helper cell responses in vaccinated patients.
   Google Scholar
• SHINTAKU I, KAWAGOE N, YUTANI Set al.: Expression of the SART1 tumor rejection antigen in renal cell carcinoma. Urol. Res. (2000) 28 (3) : 178–184.
   Google Scholar
• NEUMANN E, ENGELSBERG A, DECKER J et al: Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res. (1998) 58(18):4090–4095.
   Google Scholar
• TATSUMI T, KIERSTEAD LS,RANIERI E et al.: MAGE-6 encodes HLA-DRbetal*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin. Cancer Res. (2003) 9(3):947–954.
   Google Scholar
• GAUDIN C, DIETRICH PY,ROBACHE S et al.: In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma. Cancer Res. (1995) 55(3):685–690.
   Google Scholar
• SCARDINO A, ALVES P, GROSS DA et al.: Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur.j Immunol. (2001) 31(11):3261–3270.
   PubMed Web of Science ®Google Scholar
• •The HER-2/neu proto-oncogene is overexpressed by many different carcinomas and is shown in this study to contain a number of CTL epitopes. Importantly, primed CTLs specific for these epitopes were detected in freshly isolated TILs from three RCC patients. More recent studies by the same group have demonstrated the importance of subdominant or cryptic CTL epitopes as vaccine candidates for both HER-2/neu and hTERT.
   Google Scholar
• LINEHAN WM: Molecular targeting of VHL gene pathway in clear cell kidney cancer. Urol. (2003) 170(2 Pt 1):593–594.
   Google Scholar
• MUMBERG D, WICK M,SCHREIBER H: Unique tumor antigens redefined as mutant tumor-specific antigens. Semin. Immunol. (1996) 8(5):289–293.
   PubMedGoogle Scholar
• KUNDIG TM, BACHMANN ME OEHEN S et al.: On the role of antigen in maintaining cytotoxic T-cell memory. Proc. Nati Acad. St". USA (1996) 93(18):9716–9723.
   Google Scholar
• GILBOA E, VIEWEG J: Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev (2004) 199:251–263.
   PubMed Web of Science ®Google Scholar
• BOCZKOWSKI D, NAIR SK, NAM JH,LYERLY HK, GILBOA E: Induction of tumor immunity and cytotoxicT lymphocyte responses using dendritic cells transfected with messenger RNAamplified from tumor cells. Cancer Res. (2000) 60(4):1028–1034.
   PubMed Web of Science ®Google Scholar
• •See [15].
   Google Scholar
• HEISER A, MAURICE MA, YANCEY DRet al.: Induction of polyclonal prostate cancer specific cytotoxic T lymphocytes using dendritic cells transfected with amplified tumor RNA. .1. Immunol. (2001) 166:2953–2960.
   Google Scholar
• •In a vaccine setting, the use of tumour-derived antigens is often not possible, due to the restricted amount of tumour tissue. The above studies [14,15] circumvent this obstacle by demonstrating that virtually unlimited amounts of mRNA can be amplified by PCR techniques for use in vaccines.
   Google Scholar
• GILBOA E: The makings of a tumorrejection antigen. Immunity (1999) 56:223–229.
   Google Scholar
• MCCUNE CS, O& DONNELL RW, MARQUIS DM, SAHASRABUDHE DM: Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Irnmunother. (1990) 32(1):62–66.
   PubMed Web of Science ®Google Scholar
• JOCHAM D, RICHTER A,HOFFMAN L et al.: Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet (2004) 363(9409):594–599.
   Google Scholar
• SIMONS JW: Bioactivity of human GM-CSF gene therapy in metastatic renal cell carcinoma and prostate cancer. Hinyokika Kiyo (Acta Urologica Japonica) (1997) 43(11):821–822.
   PubMedGoogle Scholar
• SIMONS JW, JAFFEE EM, WEBER CE et al.: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. (1997) 57(8):1537–1546.
   PubMed Web of Science ®Google Scholar
• BANCHEREAU J, STEINMAN RIVI: Dendritic cells and the control of immunity. Nature (1998) 392(6673):245–252.
   PubMed Web of Science ®Google Scholar
• STEINMAN RIVI: Dendritic cells and immune-based therapies. Exp. Hematol. (1996) 24(8):859–862.
   PubMed Web of Science ®Google Scholar
• MULDERS P, TSO CL, GITLITZ B et al.:Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin. Cancer Res. (1999) 5(2):445–454.
   PubMed Web of Science ®Google Scholar
• HOLTL L, RIESER C, PAPESH C et al.: Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. Urol. (1999) 161 (3):777–782.
   Web of Science ®Google Scholar
• OOSTERWIJK-WAKKA JC, TIEMESSEN DM, BLEUMER I et al: Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a Phase I study. Immunother: (2002) 25(6):500–508.
   Web of Science ®Google Scholar
• DHODAPKAR MV, STEINMAN RM, KRASOVSKY J, MUNZ C,BHARDWAJ N: Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. Exp. Med. (2001) 193(2):233–238.
   PubMed Web of Science ®Google Scholar
• •This study suggests that immature DCs may not be optimal, but rather induce tolerance in a vaccination setting. This work highlighted the need for a better understanding of DC biology.
   Google Scholar
• MARTEN A, RENOTH S, HEINICKE T et al.: Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical Phase I/II trial in patients with metastatic renal cell carcinoma. Hum. Gene Titer. (2003) 14(5):483–494.
   PubMed Web of Science ®Google Scholar
• •Marten et al. show that it is not necessary to culture DCs from patients, but rather that allogeneic DCs from healthy donors can be used with similar efficacy. Allogeneic DCs not only provide the necessary antigen-presenting and costirnulatory environment, but their HLA-mismatch also stimulates immune responses.
   Google Scholar
• AVIGAN D, VASIR B, GONG J et al.:Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. (2004) 10(14):4699–4708.
   PubMed Web of Science ®Google Scholar
• •This study shows that fusions formed between autologous DCs and patients' tumour cells can be used to induce antiturnour immune and clinical responses in RCC.
   Google Scholar
• GONG J, APOSTOLOPOULOS V,CHEN D et al.: Selection andcharacterization of MUCl-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology (2000) 101(3):316–324.
   Google Scholar
• LIZ, DAI J, ZHENG H, LIU B,CAUDILL M: An integrated view of the roles and mechanisms of heat shock protein gp96-peptide complex in eliciting immune response. Front. Biosci. (2002) 7:d731–d751.
   PubMed Web of Science ®Google Scholar
• •See [32].
   Google Scholar
• SRI VASTAVA PK: Peptide-binding heatshock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation. Adv. Cancer Res. (1993) 62:153–177.
   PubMed Web of Science ®Google Scholar
• •See [32].
   Google Scholar
• TAMURA Y, PENG P, LIU K, DAOU M, SRI VASTAVA PK: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (1997) 278(5335):117–120.
   PubMed Web of Science ®Google Scholar
• •These manuscripts [30-32] describe how tumour-derived HSPs act as chaperones for antigenic peptides. Furthermore, preparations of tumour-derived HSPs can be used to effectively elicit immune responses specific for the original tumour without autoirnmune complications.
   Google Scholar
• COHEN L, DE MOOR C, PARKER PA, AMATO RJ: Quality of life in patients with metastatic renal cell carcinoma participating in a Phase I trial of an autologous tumor-derived vaccine. Urol. Oncol (2002) 7(3):119–124.
   PubMed Web of Science ®Google Scholar
• GILBOA E, NAIR SK, LYERLY HK: Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother. (1998) 46(2):82–87.
   PubMed Web of Science ®Google Scholar
• LIN KY, GUARNIERI FG, STAVELEY-O'CARROLL KF et al: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. (1996) 56(1):21–26.
   PubMed Web of Science ®Google Scholar
• •Until recently, much attention has been attributed to vaccines that activate CTL responses against tumour cells. However, only recently have the importance of Cal' T helper cell responses, in particular antigen-specific Cal' responses, been appreciated. Vaccines that activate bothCD8' andT cell responses totumour antigen are more effective becauseT cells not only enhance a CTLresponse, but also assist in establishing long-term T cell memory.
   Google Scholar
• SU Z, VIEWEG J, WEIZER A et al:Enhanced induction of telomerase-specific CD4+ T cells using dendritic cells transfected with RNA encoding a chimericgene product. Cancer Res. (2002) 62:5041–5048.
   PubMed Web of Science ®Google Scholar
• •This study demonstrated that a chimeric hTERT/LAMP-1 protein presented by DCs enhanced antigen-specific Cal' T cell responses in vitro.
   Google Scholar
• HEISER A, MAURICE MA, YANCEY DRet al: Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors.Cancer Res. (2001) 61(8):3388–3393.
   PubMed Web of Science ®Google Scholar
• •See [38].
   Google Scholar
• SU Z, DANNULL J, HEISER A et al.:Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. (2003) 63(9):2127–2133.
   PubMed Web of Science ®Google Scholar
• •This clinical study is important, as it shows that vaccination with tumour RNA-transfected DCs elicits both immune and clinical responses in patients with metastatic RCC. An important aspect of this study and that of Heiser [37] is that the T cell responses stimulated by the DC-RNA vaccine were polydonal and directed against several different RCC antigens.
   Google Scholar
• VONDERHEIDE RH, HAHN WC, SCHULTZE JL, NADLER LM: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity (1999) 10(6):673–679.
   PubMed Web of Science ®Google Scholar
• •The authors demonstrate that hTERT can be processed for class I presentation. Furthermore, they show that CTL responses can be generated to hTERT and that these can recognise and lyse tumour cells. Universal tumour antigens are often important to maintain the survival of tumour cells and are broadly applicable to many different types of cancer, thus making them ideal targets for vaccine development.
   Google Scholar
• COGGIN JH JR, BARSOUM AL, ROHRER JW: Tumors express both unique TSTA and crossprotective 44 kDa oncofetal antigen. Immunol Today (1998) 19(9):405–408.
   PubMedGoogle Scholar
• OOSTERWIJK E, RUITER DJ, HOEDEMAEKER PJ et al.: Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer (1986) 38(4):489–494.
   PubMed Web of Science ®Google Scholar
• •Carbonic anhydrase IX/G250 has recently been identified and has been used as a target for monoclonal antibody therapyand as a T cell antigen. The relative paucity of other RCC-specific antigens has, until recently, hampered the development of other RCC-specific defined vaccines.
   Google Scholar
• SAHIN U, TURECI 0,PFREUNDSCHUH M: Serological identification of human tumor antigens. Carr. Opin. Immunol (1997) 9(5):709–716.
   PubMed Web of Science ®Google Scholar
• BUSSEMAKERS MJ,VAN BOKHOVEN A, VERHAEGH GW et al.: DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. (1999) 59(23)5975–5979.
   Google Scholar
• VASMATZIS G, ESSAND M, BRINKMANN U, LEE B, PASTAN I: Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis. Proc. Nati Acad. Sci. USA (1998) 95(1):300–304.
   PubMed Web of Science ®Google Scholar
• SELIGER B, KELLNER R: Design of proteome-based studies in combination with serology for the identification of biomarkers and novel targets. Proteomics (2002) 2(12):1641–1651.
   PubMed Web of Science ®Google Scholar
• FINKE J, SALVUCCI KIERSTADT L, RANIERI E, STORKUS WJ: Immunologic responses to renal cell carcinoma. In: Renal Cell Carcinoma: Molecular Biology Immunology and Clinical Management. Bukowski RIVI, Novick A (Eds), Humana Press, Inc., Totowa, NJ, USA (2000):39–62.
   Google Scholar
• GRABMAIER K, VISSERS JL,DE WEIJERT MC et al: Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. hat.' Cancer (2000) 85(6):865–870.
   PubMed Web of Science ®Google Scholar
• ACHTAR MS, IBRAHIM RA,HERRIN VE et al: Vaccine therapy with tumor specific mutated VHL peptides in adult cancer patients with renal cell carcinoma. Annual Meeting Proceedings of the American Society of Clinical Oncology New Orleans, LA, USA (2004) 23:2589.
   Google Scholar
• SELIGER B, RONGCUN Y, ATKINS D et al.: HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int. Cancer (2000) 87(3)349–359.
   Google Scholar
• BROSSART P, STUHLER G, FLAD T et al.: Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by IP vitro induced specific cytotoxic T lymphocytes. Cancer Res. (1998) 58(4):732–736.
   PubMed Web of Science ®Google Scholar
• BROSSART P, HEINRICH KS, STUHLER G et al.: Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood (1999) 93(12):4309–4317.
   PubMed Web of Science ®Google Scholar
• BROSSART P, WIRTHS S, STUHLER G et al.: Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood (2000) 96(9):3102–3108.
   PubMed Web of Science ®Google Scholar
• PARDOLL DM, TOPALIAN SL: The roleof CD4+ T cell responses in antitumor immunity. Carr. Opin. Immunol (1998) 10:588–594.
   PubMed Web of Science ®Google Scholar
• NESTLE FO, BANCHEREAU J, HART D: Dendritic cells: on the move from bench to bedside. Nat. Med. (2001) 7(7):761–765.
   PubMed Web of Science ®Google Scholar
• SELIGER B, HOHNE A, KNUTH A et al.: Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res. (1996) 56(8):1756–1760.
   PubMed Web of Science ®Google Scholar
• •See [56].
   Google Scholar
• SELIGER B, WOLLSCHEID U,MOMBURG F, BLANKENSTEIN T, HUBER C: Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res. (2001) 61(3):1095–1099.
   PubMed Web of Science ®Google Scholar
• •These manuscripts [55,56] demonstrate important deficiencies in the antigen-processing machinery (APM) of tumour cells. Tumour cells can avoid presenting key target peptides by downregulating the expression of specific APM components (e.g., TAP molecules), or escape immune attack by downregulating expression of specific HLA alleles.
   Google Scholar
• VALMORI D, DUTOIT V, AYYOUB M et al.: Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.Cancer Litman. (2003) 3:15.
   PubMedGoogle Scholar
• •See [58].
   Google Scholar
• SLINGLUFF CL JR, PETRONI GR,YAMSHCHIKOV GV et al.: Clinical and immunologic results of a randomized Phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.Clin. Oncol (2003) 21(21):4016–4026.
   Google Scholar
• •These manuscripts [57,58] demonstrate that it is possible to simultaneously elicitmultiple CTL responses by combining several peptide vaccines either alone or when pulsed onto DCs. This work addresses one of the major short-comings of vaccination with single tumour peptides - the evolution of antigen-loss variants.
   Google Scholar
• NAIR SK, BOCZKOWSKI D, MORSE M et al.: Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes M vitro using human dendritic cells transfected with RNA. Nat. Biotechnol (1998) 16(4):364–369.
   PubMed Web of Science ®Google Scholar
• HEISER A, DAHM P, YANCEY D et al:Human dendritic cells transfected with RNA encoding prostate specific antigen stimulate prostate specific CTL responses in vitro. j Immunol (2000) 164:5508–5514.
   PubMed Web of Science ®Google Scholar
• NAIR SK, HULLS, COLEMAN D et al: Induction of carcinoembryonic antigen (CEA) -specificcytotoxic T-lymphocyte responses M vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int. .1. Cancer (1999) 82(1):121–124.
   Google Scholar
• HEISER A, COLEMAN D, DANNULL J et al.: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. (2002) 109(3):409–417.
   PubMed Web of Science ®Google Scholar
• SU Z, VIEWEG JW, DANNULL J, DAHM P: Vaccination of metastatic prostate cancer patients using mature dendritic cells transfected with mRNA encoding hTERT or an MHC class II targeted hTERT/LAMP fusion protein: results from a Phase I clinical trial. Annual Meeting Proceedings of the American Society of Clinical Oncology New Orleans, LA, USA (2004) 23:2507.
   Google Scholar
• •This clinical study is important because it is the first of its kind to apply hTERT mRNA-transduced mature DCs in cancer patients. The vaccine not only induced concomitant Cal' and CD8+ T cell responses, but was also found to alter surrogate clinical indicators byprolonging the PSA-doubling time for a subgroup of patients.
   Google Scholar
• VONDERHEIDE RH, DOMCHEK SM, SCHULTZE JL et al: Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin. Cancer Res. (2004) 10(3):828–839.
   PubMed Web of Science ®Google Scholar
• NAIR SK, HEISER A, BOCZKOWSKI D et al.: Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat. Med. (2000) 6:1011–1017.
   PubMed Web of Science ®Google Scholar
• SIEGEL S, WAGNER A, SCHMITZ N, ZEIS M: Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br. J. Haematol (2003) 122 (6):911–914.
   PubMed Web of Science ®Google Scholar
• •See [67].
   Google Scholar
• ZEIS M, SIEGEL S, WAGNER A et al:Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.Immunol (2003) 170(11):5391–5397.
   Web of Science ®Google Scholar
• •The above manuscripts [66,67]demonstrate the induction of antiturnour immune responses to the non-mutated universal antigen survivin. Survivin is an inhibitor of apoptosis and is abundantly expressed by a wide range of malignancies. In addition to being an RCC antigen, survivin is considered a potentially potent CTL target, as downregulation or antigen-loss as a mechanism ofimmune escape would hinder tumour growth and progression.
   Google Scholar
• SHAY JVV, BACCHETTI S: A survey of telomerase activity in human cancer. Ear. J. Cancer (1997) 33(5):787–791.
   PubMed Web of Science ®Google Scholar
• VELCULESCU VE, MADDEN SL, ZHANG L et al.: Analysis of human transcriptomes. Nat. Genet. (1999) 23(4):387–388.
   PubMed Web of Science ®Google Scholar
• ZELLE-RIESER C, BARSOUM AL, SALLUSTO F et al.: Expression and immunogenicity of oncofetal antigen-immature laminin receptor in human renal cell carcinoma. J. Urol. (2001) 165(5):1705–1709.
   PubMed Web of Science ®Google Scholar
• FONG GH, ROSSANT J,GERTSENSTEIN M, BREITMAN ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature (1995) 376 (6535):66–70.
   PubMed Web of Science ®Google Scholar
• NELSON AR, FINGLETON B, ROTHENBERG ML, MATRISIAN LM: Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol (2000) 18(5):1135–1149.
   PubMed Web of Science ®Google Scholar
• NAIR S, BOCZKOWSKI D, MOELLER B et al.: Synergy betweentumor immunotherapy and antiangiogenictherapy. Blood (2003) 102(3):964–971.
   PubMed Web of Science ®Google Scholar
• •This work demonstrates the potential for combining vaccination against tumour and stromal antigens.
   Google Scholar
• SU JM, WET YQ, TIAN L et al.: Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res. (2003) 63(3):600–607.
   PubMed Web of Science ®Google Scholar
• WET YQ, WANG QR, ZHAO X et al: Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat. Med. (2000) 6(10):1160–1166.
   PubMed Web of Science ®Google Scholar
• •See [77].
   Google Scholar
• LT Y, WANG MN, LT H et al: Activeimmunization against the vascular endothelial growth factor receptor flkl inhibits tumor angiogenesis and metastasis. J. Exp. Med. (2002) 195(12):1575–1584.
   PubMed Web of Science ®Google Scholar
• •See [77].
   Google Scholar
• NIETHAMMER AG, XIANG R,BECKER JC et al.: A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. (2002) 8(12):1369–1375.
   Google Scholar
• •These references [75-77] show that tolerance against vascular endothelium canbe broken by a range of different vaccination strategies, and that the ensuing T cell responses inhibit tumour growth by preventing angiogenesis. Thus far, it was unknown that CTL precursors specific for endothelial-specific targets existed or if they could be activated by vaccination.
   Google Scholar
• MELIEF CJ, TOES RE, MEDEMA JP, VAN DER BURG SH, OSSENDORP F, OFFRINGA R: Strategies for immunotherapy of cancer. Adv. bronunol (2000) 75:235–282.
   PubMed Web of Science ®Google Scholar
• QIN Z, BLANKENSTEIN T: CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Innnunio, (2000) 12(6):677–686.
   Google Scholar
• MUMBERG D, MONACH PA, WANDERLING S et al: CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. Natl. Acad. Sci. USA (1999) 96(15):8633–8638.
   PubMed Web of Science ®Google Scholar
• VISSERS JL, DE VRIES IJ, ENGELEN LPet al: Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyteantigen-DR molecules to CD4(+)T lymphocytes. Int. J. Cancer (2002) 100(4):441–444.
   PubMed Web of Science ®Google Scholar
• WU T-C, GUARNIER FG, STAVELEY-O'CARROLL KF et al.: Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl. Acad. Sci. USA (1995) 92:11671–11675.
   Google Scholar